Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Verastem, Inc.
Sponsor:
Information provided by (Responsible Party):
Verastem, Inc.
ClinicalTrials.gov Identifier:
NCT01870609
First received: May 29, 2013
Last updated: August 13, 2014
Last verified: August 2014
  Purpose

This study is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of defactinib (VS-6063) in subjects with malignant pleural mesothelioma (MPM) who have not progressed (confirmed partial response or stable disease) following ≥ 4 cycles of treatment with pemetrexed/cisplatin or pemetrexed/carboplatin. Prior to entry and randomization to the study, each subject must have tumor Merlin status(high or low) established by immunohistochemistry performed at a central laboratory. Subjects will be randomized in a 1:1 ratio to receive oral VS-6063 400 mg twice per day, or matched placebo. Randomization will be stratified by tumor Merlin status (high versus low). Progression will be assessed both locally and by central review using the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1. Subjects will continue to receive treatment until disease progression or other discontinuation criteria are met. Following documentation of nonfatal disease progression, all subjects will be followed for overall survival by telephone contact every 2 months until end of life or the close of the study.


Condition Intervention Phase
Malignant Pleural Mesothelioma
Drug: defactinib (VS-6063)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Resource links provided by NLM:


Further study details as provided by Verastem, Inc.:

Primary Outcome Measures:
  • Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo [ Time Frame: From randomization to end of life, an expected average of 12 months ] [ Designated as safety issue: No ]
    The median duration of OS will be estimated based on the 50th percentile of the Kaplan-Meier distribution

  • Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo [ Time Frame: From date of randomization to earliest documented date of progression, an expected average of 4 months ] [ Designated as safety issue: No ]
    PFS will be calculated based on the stratified log-rank test, and will use Kaplan-Meier estimation methods for estimation of summary statistics


Secondary Outcome Measures:
  • To assess Quality of Life (QoL) in subjects treated with defactinib (VS-6063) or placebo using the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso) [ Time Frame: Every 3-4 weeks from baseline through end of treatment, an expected average of 4 months ] [ Designated as safety issue: No ]
    QoL will be assessed using the LCSS-Meso. The LCSS-Meso total score will be analyzed through a comparison of median area under the curve (AUC) between the 2 treatment groups using a Wilcoxon test.

  • To determine the objective response rate (ORR) in subjects receiving defactinib (VS-6063) or placebo. [ Time Frame: Every 6-8 weeks from baseline through end of treatment, an expected average of 4 months ] [ Designated as safety issue: No ]
    ORR is measured as the best overall response assessed by central review using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1.


Other Outcome Measures:
  • Determine the time to new lesion in subjects receiving defactinib (VS-6063) or placebo [ Time Frame: Every 6-8 weeks from baseline until end of treatment, an expected average of 4 months ] [ Designated as safety issue: No ]
    Time to new lesion will be calculated from the date of randomization to the time of CT scan documenting a new lesion or date of other unambiguous indicator of new lesion development.

  • Evaluate the relationship of defactinib (VS-6063) pharmacokinetics (PK) and outcome [ Time Frame: Time points at Week 4, Week 7, Week 10 and Week 13 ] [ Designated as safety issue: No ]
    PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2, compared with outcome

  • Evaluate the population pharmacokinetics of defactinib (VS-6063) in subjects with malignant pleural mesothelioma [ Time Frame: Time points at Week 4, Week 7, Week 10 and Week 13 ] [ Designated as safety issue: No ]
    PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2

  • Evaluate the safety and tolerability of defactinib (VS-6063) in subjects with malignant pleural mesothelioma [ Time Frame: From start of treatment to end of treatment, an expected average of 4 months ] [ Designated as safety issue: Yes ]
    Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03

  • To collect EuroQol 5-Dimensional Health Questionnaire (EQ-5D) for health economics purposes [ Time Frame: Every 3-4 weeks from baseline through end of treatment, an expected average of 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 372
Study Start Date: September 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: defactinib (VS-6063)
2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
Drug: defactinib (VS-6063)
Placebo Comparator: Placebo
2 placebo tablets, administered orally, twice daily
Drug: Placebo
Sugar pill manufactured to mimic defactinib tablet

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Able to understand and give written informed consent and comply with study procedures.
  • 2. Histologically proven diagnosis of MPM. All subjects must have biopsy material (archival tissue is acceptable) available for immunohistochemistry determination of Merlin status prior to enrollment.
  • 3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.
  • 4. Received only one prior chemotherapy regimen consisting of ≥ 4 cycles of pemetrexed/cisplatin or pemetrexed/carboplatin; subjects must have documentation of an ongoing response (confirmed PR or SD) following completion of this regimen. Subjects changing from cisplatin to carboplatin or vice versa within the same course of treatment because of platinum toxicity will be considered to have had first-line chemotherapy. Note: Subjects may have undergone previous surgical resection of their disease providing it was completed prior to initiation of chemotherapy.
  • 5. Received last dose of prior chemotherapy within ≤ 6 weeks of first dose of VS-6063.
  • 6. Have completed baseline quality of life evaluation as assessed by LCSS modified for mesothelioma
  • 7. Age ≥18 years.
  • 8. Life expectancy ≥3 months.
  • 9. All prior cytotoxic toxicities must have resolved to grade ≤ 1 prior to randomization.
  • 10. Performance status according to the Karnofsky Scale of ≥ 70% (after palliative measures such as pleural drainage).
  • 11. Corrected QT interval (QTc) < 470 ms (as calculated by the Fridericia correction formula).
  • 12. Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; absolute neutrophil count [ANC] ≥ 1.5 x 109/L) without the use of hematopoietic growth factors.
  • 13. Adequate renal function (creatinine ≤ 1.5 x ULN [upper limit of normal] or glomerular filtration rate of ≥ 50mL/min).
  • 14. Adequate hepatic function (total bilirubin ≤ 1.5 x ULN for the institution; aspartate transaminase [AST] and alanine transaminase [ALT] ≤ 2.5 x ULN).
  • 15. Men and women of childbearing potential must agree to use adequate contraception(double barrier birth control) for the duration of study therapy and for 3 months after the last dose of VS-6063.

Exclusion Criteria:

  • 1. Currently enrolled in (or completed within 30 days before study drug administration)another investigational drug study.
  • 2. GI condition that could interfere with the swallowing or absorption of study drug.
  • 3. History of upper GI bleeding, ulceration, or perforation within 12 months prior to the first dose of study drug.
  • 4. Known history of Gilbert's Syndrome.
  • 5. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
  • 6. Subjects with known infection with human immunodeficiency virus or Acquired Immune Deficiency Syndrome (testing not required).
  • 7. Subjects with known infection with hepatitis A, B or C (testing not required).
  • 8. Any evidence of serious active infections.
  • 9. Major surgery within 28 days prior to the first dose of study drug.
  • 10. Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases). Stable brain metastases either previously treated or being treated with a stable dose of steroids and/or anticonvulsants (no dose change within 28 days prior to the first dose of study drug) will be allowed.
  • 11. Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
  • 12 Known history of malignant hypertension.
  • 13. Psychiatric illness or social situations that would limit compliance with study requirements.
  • 14. History of another invasive malignancy in the last 5 years. Adequately treated noninvasive,non-melanoma skin cancers as well as in situ carcinoma of the cervix within the last 5 years will be allowed.
  • 15. Prior treatment with drugs an FAK inhibitor.
  • 16. Women who are pregnant or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01870609

  Hide Study Locations
Locations
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States
Contact: Jennifer Hull, RN, OCN    773-834-3137      
Principal Investigator: Dr. Hedy Kindler         
United States, Maryland
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Recruiting
Baltimore, Maryland, United States
Contact: Ronan Kelly    443-287-0005      
Contact: Charles Raines    410-502-3696      
Principal Investigator: Dr. Julie Brahmer         
United States, New York
Jacobi Medical Center Recruiting
Bronx, New York, United States, 10461
Contact: Claudia Calderon, RN    718-918-3577      
Principal Investigator: Dr. Richard Gralla         
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Dr. Marjorie Zauderer, MD    646-888-4656      
Principal Investigator: Dr. Marjorie Zauderer         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States
Contact: Dr. James Stevenson, MD    216-636-6888      
Principal Investigator: Dr. James Stevenson         
United States, Pennsylvania
Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Mona Jacobs-Small    215-662-8632    Mona.Jacobs-Small@uphs.upenn.edu   
Principal Investigator: Dr. Evan Alley         
United States, Texas
UT Southwestern Recruiting
Dallas, Texas, United States
Contact: Laurin Priddy    214-648-1688      
Principal Investigator: Dr. Jonathan Dowell         
Australia, Western Australia
Sir Charles Gairdner Hospital Recruiting
Perth, Western Australia, Australia
Contact: Judy Innes-Rowe    08 63833280      
Principal Investigator: Prof. Anna Nowak         
Australia
Northern Cancer Institute Recruiting
Sydney, Australia
Contact: Sally McCowatt    02 9463 1181      
Principal Investigator: Dr. Nick Pavlakis         
Belgium
UCL - St. Luc Recruiting
Brussel, Belgium
Contact: Vanessa Erculisse       Vanessa.Erculisse@uclouvain.be   
Principal Investigator: Prof. Thierry Pieters         
Antwerp University Hospital Recruiting
Edegem, Belgium
Contact: Ann Decoene    +32 3 8214719    ann.decoene@uza.be   
Principal Investigator: Prof. Jan Van Meerbeeck         
Canada, Ontario
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada
Contact: Andrea Foster    (416) 946-4501 ext 5010      
Principal Investigator: Dr. Ron Feld         
France
CHRU, Lille Recruiting
Lille, France
Contact: Prof. Arnaud Scherpereel    00 33 3 20 44 56 12      
Principal Investigator: Prof. Arnaud Scherpereel         
Hôpitaux de Marseille Recruiting
Marseille, France
Contact: Dr. Laurent Greillier    00 33 4 91 96 59 01      
Principal Investigator: Dr. Laurent Greillier         
Gustave Roussy Recruiting
Villejuif, France
Contact: Dr. Planchard    00 33 1 42 11 45 64      
Principal Investigator: Dr. David Planchard         
Japan
Hiroshima University Hospital Recruiting
Hiroshima, Japan
Contact: Yoshihiro Miyata    81-82-257-5869      
Principal Investigator: Prof. Morihito Okada         
Hyogo College of Medicine Recruiting
Hyogo, Japan
Contact: Dr. Taiichiro Otsuki    +81-798-45-6596      
Principal Investigator: Prof. Takashi Nakano         
Okayama Rousai Hospital Recruiting
Okayama, Japan
Contact: Dr. Nobukazu Fujimoto    81-86-262-0131      
Principal Investigator: Dr. Takumi Kishimoto         
Netherlands
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Recruiting
Amsterdam, Netherlands
Contact: Marianne Mahn    +31(0)205127496    m.mahn@nki.nl   
Principal Investigator: Prof. Paul Baas         
Medisch Spectrum Twente, Enschede Recruiting
Enschede, Netherlands
Contact: Ms. M. Mulder, MSc    +31 6 31 67 58 46    M.Mulder@mst.nl   
Principal Investigator: Dr. J. H. Schouwink         
Erasmus MC Recruiting
Rotterdam, Netherlands
Contact: Mrs. A. L. Geel    +31 (0)107030323    a.geel@erasmusmc.nl   
Principal Investigator: Dr. Joachim G.J.V. Aerts         
New Zealand
Auckland Oncology Research Centre Recruiting
Auckland, New Zealand
Contact: Vivian Sun       Vsun@adhb.govt.nz   
Principal Investigator: Dr. Richard Sullivan         
Spain
Vall d'Hebron University Hospital Recruiting
Barcelona, Spain
Contact: Marta Malo Perez    +34 93 274 60 00 ext 4375      
Principal Investigator: Dr. Susana Cedres         
Institut Oncològic del Vallés Consorci Hospitalari Parc Tauli Recruiting
Barcelona, Spain
Contact: Jose Garcia Ruiz    +34 93 724 00 84      
Principal Investigator: Dr. Yolanda García García         
Ensayos Clínicos Oncología Recruiting
Madrid, Spain
Contact: Dr. Santiago Ponce    +34 91 469 23 13      
Contact: Irene Diaz    +34 91 469 23 13      
Principal Investigator: Dr. Santiago Ponce Aix         
Hospital Madrid Norte- Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC) Recruiting
Madrid, Spain
Contact: Rocio Blanco    +34 91 756 79 84 ext 4885      
Principal Investigator: Dr. Cristobal Belda-Iniesta         
Sweden
Skane University Hospital Recruiting
Lund, Sweden
Contact: Dr. Ronny Ohman    : +46 (0)46 17 10 00      
Principal Investigator: Dr. Ronny Ohman         
Karolinska University Hospital Recruiting
Stockholm, Sweden
Contact: Gunnar Hillerdal    +46 (0)8 517 700 00      
Principal Investigator: Dr. Daniel Brodin         
University Hospital Recruiting
Uppsala, Sweden
Contact: Dr. Simon Ekman    +46 (0)18 611 00 00      
Principal Investigator: Dr. Simon Ekman         
United Kingdom
Southmead Hospital Recruiting
Bristol, United Kingdom
Contact: Deborah Warbrick       Deborah.Warbrick@nbt.nhs.uk   
Principal Investigator: Dr. Jeremy Braybrooke         
Addenbrooke's Hospital Recruiting
Cambridge, United Kingdom
Contact: Marian Coliof    +44 (0)1223 216083    cctc@addenbrookes.nhs.uk   
Principal Investigator: Dr. David Gilligan         
Velindre Hospital Cardiff Recruiting
Cardiff, United Kingdom
Contact: Amanda Jackson    +44 (0)2920 615888 ext 6315    Amanda.Jackson2@wales.nhs.uk   
Principal Investigator: Dr. Jason Lester         
Broomfield Hospital Recruiting
Chelmsford, United Kingdom, CM1 7ET
Contact: Lyndsay Johnson    01254 516 339    lyndsay.johnson@meht.nhs.uk   
Principal Investigator: Dr. Sunil Skaria         
Beatson Oncology Centre Recruiting
Glasgow, United Kingdom
Contact: Julie Lang       julie.lang@ggc.scot.nhs.uk   
Principal Investigator: Dr. Noelle O'Rourke         
University of Leicester Recruiting
Leicester, United Kingdom
Contact: Anita Kang    +44 (0)116 258 7598    Anita.Kang@uhl-tr.nhs.uk   
Contact: Debbie Samuel    0116 204 7872    debbie.samuel@uhl-tr.nhs.uk   
Principal Investigator: Prof. Dean Fennell         
Guys Hospital Recruiting
London, United Kingdom
Contact: Dr. James Spicer, MD    +44 (0) 207188 4260      
Principal Investigator: Dr. James Spicer, MD         
St. Bartholomew's Hospital Recruiting
London, United Kingdom
Contact: Dr. Jeremy Steele    +44 7957645383    Jeremy.steele@bartshealth.nhs.uk   
Principal Investigator: Dr. Jeremy Steele         
Wythenshawe Hospital Recruiting
Manchester, United Kingdom
Contact: Dr. Paul Taylor    +44 (0)161 291 2829    paul.taylor@uhsm.nhs.uk   
Principal Investigator: Dr. Paul Taylor         
Freeman Hospital Recruiting
Newcastle, United Kingdom
Contact: Chris Barron    0191 213 8436    chris.barron@nuth.nhs.uk   
Principal Investigator: Dr. Andrew Hughes         
Southampton General Hospital Recruiting
Southampton, United Kingdom
Contact: Dr. Luke Nolan    +44 (0)23 8079 6802      
Principal Investigator: Dr. Luke Nolan         
Sponsors and Collaborators
Verastem, Inc.
  More Information

No publications provided

Responsible Party: Verastem, Inc.
ClinicalTrials.gov Identifier: NCT01870609     History of Changes
Other Study ID Numbers: VS-6063-202
Study First Received: May 29, 2013
Last Updated: August 13, 2014
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
New Zealand: Medsafe
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Belgium: Federal Agency for Medicinal Products and Health Products
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Netherlands: Medicines Evaluation Board (MEB)
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
South Africa: Medicines Control Council
Canada: Health Canada
Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Mesothelioma
Neoplasms, Mesothelial
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on August 21, 2014